Long-term outcome of individuals treated with oral insulin: Diabetes Prevention Trial-Type 1 (DPT-1) oral insulin trial

Diabetes Care

Volumn 34, Issue 7, 2011, Pages 1585-1590

  Vehik, Kendra ^a   Cuthbertson, David ^a   Ruhlig, Holly ^a   Schatz, Desmond A ^b   Peakman, Mark ^c,d   Krischer, Jeffrey P ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; HEMOGLOBIN A1C; INSULIN; PLACEBO; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN ANTIBODY;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREAS ISLET CELL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TELECONSULTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FAMILY HEALTH; GENETICS; GLUCOSE TOLERANCE TEST; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADOLESCENT; AUTOANTIBODIES; CHILD; DIABETES MELLITUS, TYPE 1; FAMILY HEALTH; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; MALE; PLACEBOS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 80054692681     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0523     Document Type: Article

References (22)

1. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
2. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
3. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92 (Pubitemid 46075008)
4. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. The Trial Net Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104
5. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006;13:143-157 (Pubitemid 44950033)
6. Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007;148:17-31 (Pubitemid 46364996)
7. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells: they're back and critical for regulation of autoimmunity! Immunol Rev 2001;182:149-163 (Pubitemid 33070215)
8. Waldmann H, Cobbold S. Regulating the immune response to transplants: a role for CD4+ regulatory cells? Immunity 2001;14:399-406 (Pubitemid 32441592)
9. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25:195-201 (Pubitemid 44224153)
10. Laliotou B, Duncan L, Dick AD. Intranasal administration of retinal antigens induces transient T cell activation and apoptosis within drainage lymph nodes but not spleen. J Autoimmun 1999;12:145-155 (Pubitemid 29223046)
11. Arif S, Tree TI, Astill TP, et al. Auto-reactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004;113:451-463 (Pubitemid 38544189)
12. Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J Immunol 1999;163:1833-1838 (Pubitemid 29382182)
13. Petersen JS, Bregenholt S, Apostolopolous V, et al. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin Exp Immunol 2003;134:38-45 (Pubitemid 37186585)
14. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 2010;22:609-615
15. Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev 1993;9:279-287 (Pubitemid 24160207)
16. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 1998;47:39-44 (Pubitemid 28030805)
17. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun 1994;7:655-663 (Pubitemid 24327697)
18. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991;88:10252-10256 (Pubitemid 21915813)
19. Chaillous L, Lefèvre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet 2000;356:545-549 (Pubitemid 30611859)
20. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). Diabetologia 2000;43:1000-1004 (Pubitemid 30655719)
21. Ergun-Longmire B, Marker J, Zeidler A, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann N Y Acad Sci 2004;1029: 260-277 (Pubitemid 40298536)
22. Santamaria P. The long and winding road to understanding and conquering type 1 diabetes. Immunity 2010;32:437-445